Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.

Next Previous
Trial Profile

A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GBS NN (Primary) ; Aluminium hydroxide
  • Indications Streptococcal infections
  • Focus Adverse reactions
  • Acronyms NeoStrep
  • Sponsors Minervax

Most Recent Events

  • 29 Jun 2021 Results published in the Vaccine
  • 01 Nov 2017 Planned End Date changed from 1 Mar 2018 to 21 Apr 2017.
  • 01 Nov 2017 Planned primary completion date changed from 1 Mar 2016 to 12 Apr 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top